Pay in 4 interest-free payments of $6.90 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Launched by Eli Lilly in late 2023, Zepbound combines GLP-1 and GIP receptor agonism to deliver superior weight loss compared to single agonists
Food and Drug Administration (FDA), has fostered an estimated $2.2 billion underground market
The STEP trials are testing semaglutide at the higher dose of 2.4 mg/week (as compared to 1.0 mg/week for the original diabetes indication), specifically for promoting weight loss, regardless of the presence of type 2 diabetes
Are You Selenium Deficient
(Jalleh and colleagues, review, Journal of Clinical Investigation , 2026.) Sudden vision loss (a condition called NAION) is the scary headline
US$ 29.19
US$ 22.52
US$ 26.30
US$ 27.05
![Multimodal Rehabilitation Improves Erectile Function and Quality of Life in Men with Hard Flaccid Syndrome[v1]](https://www.preprints.org/frontend/picture/ms_xml/manuscript/142677f6504c2685a0e113381b490a94/preprints-213447-g001.png)
US$ 24.53
US$ 20.70
